We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Researchers Recommend the Membrane Protein Flotillin as a Biomarker for Alzheimer’s Disease

By LabMedica International staff writers
Posted on 12 Nov 2019
Print article
Image: Serum flotillin levels in patients with AD were lower than those in non-AD cases (Photo courtesy of Makoto Michikawa, Nagoya City University)
Image: Serum flotillin levels in patients with AD were lower than those in non-AD cases (Photo courtesy of Makoto Michikawa, Nagoya City University)
A team of Japanese researchers have suggested adding the protein flotillin to the arsenal of biomarkers that can be used to diagnose Alzheimer’s disease.

Flotillins are membrane proteins that form microdomains in the plasma membrane of all mammalian cell types studied to date. They span the evolutionary spectrum, with proteins related to flotillins present in bacteria, fungi, plants, and metazoans, which suggests that they perform important, and probably conserved, functions. Flotillins have been implicated in myriad processes that include endocytosis, signal transduction, and regulation of the cortical cytoskeleton, yet the molecular mechanisms that underlie flotillin function in these different cases are still poorly understood.

Investigators at Nagoya City University (Japan) had shown previously that flotillin release was reduced by amyloid beta (Abeta), a well known Alzheimer’s disease (AD) biomarker. Therefore, they designed the current study to determine whether flotillin levels would be reduced in the cerebral spinal fluid (CSF) and/or serum of patients with AD.

For this study, the investigators used western blotting to analyze flotillin levels in the CSF and serum of non-AD controls and of patients with AD and mild cognitive impairment (MCI). Flotillin levels in cerebroventricular fluid (CVF) and serum of AD, vascular dementia (VaD), and non-AD autopsy cases were also analyzed.

Results revealed that flotillin levels were significantly lower in the CSF and serum of AD patients compared with those of non-AD controls. Moreover, in patients with MCI due to AD, CSF and serum flotillin levels were significantly decreased compared with those of patients with MCI not due to AD. Flotillin levels remained unchanged in CVF and serum of autopsy cases diagnosed as VaD. Serum flotillin level was negatively associated with deposition of amyloid plaques in the brain.

The investigators postulated that these results, which were published in the October 29, 2019, online edition of the Journal of Alzheimer's Disease, demonstrated that serum flotillin level could serve as one of the blood markers for estimation of brain amyloid deposition and early diagnosis of AD.

Related Links:
Nagoya City University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.